Giacobello Scott M. 4

What Happened
Scott M. Giacobello, Chief Financial Officer of Whitehawk Therapeutics (WHWK), had 6,750 restricted stock units (RSUs) convert to common stock on March 1, 2026, and then sold 2,594 shares in an open-market transaction on March 2, 2026 at $3.31 per share, generating $8,585. The filing also reports a disposition of 6,750 shares tied to the RSU conversion (reported at $0), which reflects shares surrendered/withheld in connection with the vesting event.

Key Details

• Transaction dates/prices:
  • 2026-03-01: Conversion of 6,750 RSUs into common stock (reported as acquired).
  • 2026-03-01: Disposition of 6,750 shares related to the derivative conversion (reported at $0).
  • 2026-03-02: Open-market sale of 2,594 shares at $3.31 each, total proceeds $8,585.
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• Footnotes:
  • F1: Each RSU converts to one share of common stock.
  • F2: The sale represents a broker-assisted sale to satisfy the Reporting Person’s tax withholding obligations tied to RSU vesting.
  • F3: RSUs vest per a schedule beginning March 1, 2024 (25% each year over four years).
• Filing timeliness: Form 4 was filed March 10, 2026 reporting March 1–2 transactions; this appears to be after the typical two-business-day Form 4 deadline.

Context
This was primarily a vesting/conversion of RSUs with associated share withholding and a small open-market sale to cover taxes — a routine, non-speculative transaction common after equity awards vest. The derivative activity reflects RSU conversion (not a market purchase). No 10% owner status or 10b5-1 plan is indicated in the provided excerpt.